TG Therapeutics, Inc.

As of June 30, 2026, TG Therapeutics, Inc. carries a market capitalization of 7.39B, placing it among publicly traded companies globally. Its enterprise value stands at 7.57B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

TG Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, TG Therapeutics, Inc. has 153.08M shares outstanding.

As of June 30, 2026, TG Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 17.95. The price-to-sales ratio is 9.91, and the price-to-book ratio stands at 13.98.

As of June 30, 2026, TG Therapeutics, Inc. trades at an EV/EBITDA multiple of 63.30 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 63.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 7.57B versus a market cap of 7.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, TG Therapeutics, Inc. maintains a current ratio of 4.27, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 124.89, indicating elevated leverage, while an interest coverage ratio of 3.64 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, TG Therapeutics, Inc. posted a return on equity (ROE) of 100.28, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 37.70, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.82M in revenue per employee across its workforce of 383.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.93 indicates how many times TG Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, TG Therapeutics, Inc. recorded an income tax benefit of -297.51M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 88.93M, leaving 386.44M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, TG Therapeutics, Inc.'s stock has gained approximately 58.10% over the past 52 weeks. The 50-day moving average sits at 47.77, while the 200-day moving average is 37.57.

Over the twelve months ended June 30, 2026, TG Therapeutics, Inc. generated 699.83M in revenue and converted that into 386.44M in net income, yielding earnings per share of 2.42. EBITDA reached 119.59M, while operating income came in at 119.33M.

As of June 30, 2026, TG Therapeutics, Inc. holds 483.38M in cash and equivalents against 660.36M in total debt, resulting in a net debt position of 230.04M. Total book value stands at 528.75M, with working capital of 767.81M providing operational flexibility.

TG Therapeutics, Inc. produced 15.65M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -429,772.30 in capital expenditures, free cash flow totaled 15.22M - equivalent to 0.11 per share.

Over the twelve months ended June 30, 2026, TG Therapeutics, Inc. posted a gross margin of 82.37, reflecting its pricing power and cost economics. The operating margin of 17.05 and net profit margin of 55.22 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, TG Therapeutics, Inc. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 0.20, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -3.71, meaning TG Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

TG Therapeutics, Inc.'s most recent stock split took place on April 30, 2012 with a 225:4 split ratio.

As of June 30, 2026, TG Therapeutics, Inc. has an Altman Z-Score of 5.40, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.